Dosimetric impact of bladder filling on organs at risk with barium contrast in the small bowel for adjuvant vaginal cuff brachytherapy

María del Carmen Salas Buzón, PhD1, Lucía Gutiérrez Bayard, PhD1, Raquel Rodríguez Sanchez, MD1, Luis Ángel Quiñones Rodríguez, MD2, Sarah Sayago Gil, MD1, Cristina Muñoz Higuera, MD1
1Radiation Oncology Department, Puerta del Mar University Hospital, Cádiz, Spain, 2Radiophysics Department, Puerta del Mar University Hospital, Cádiz, Spain

Abstract

Purpose: The aim of this prospective study was to analyze dosimetric impact of modifying bladder filling on dose distribution in organs at risk (OARs) when using contrast in the small bowel of patients under adjuvant therapy with high-dose-rate vaginal cuff brachytherapy (HDR-VCB) for endometrial cancer.

Material and methods: This research included 19 patients who underwent laparoscopic surgery. They were treated with HDR-VCB and 2.5-3.5 cm diameter cylinders. Two successive computerized tomography (CT) scans were performed, with empty bladder and with bladder filled with 180 cc of saline solution. Bladder, rectum, sigmoid, and small bowel were delineated as OARs. Oral barium contrast was used to clearly visualize small bowel loops. Prescription dose was 7 Gy. Dose-volume histograms were generated for each OAR, with full and empty bladder to compare doses received.

Results: Bladder distension had no dosimetric impact on the bladder, rectum, or sigmoid, unlike the small bowel. With full bladder, mean minimum dose at 2 cc ($D_{2cc}$) was not significantly higher for full vs. empty bladder (5.56 vs. 5.06 Gy, $p = 0.07$), whereas there was a significant reduction in the small bowel (1.68 vs. 2.70 Gy, $p < 0.001$). With full bladder, the dose increased to 50% of the volume ($D_{50\%}$) of the bladder (2.11 vs. 1.28 Gy, $p < 0.001$), and decreased in the small bowel (0.70 vs. 1.09 Gy, $p < 0.001$).

Conclusions: The present study describes the dose received by organs at risk during HDR-VCB, making it possible to define the dose received by small bowel loops, when visualized with oral barium contrast. In patients undergoing laparoscopic surgery, a full bladder during HDR-VCB reduces the dose to the small bowel without a clinically relevant dose increase in the bladder, and no dose increase in other OARs.

Key words: endometrial cancer, vaginal cuff brachytherapy, small bowel, bladder distention, barium.

Purpose

Endometrial carcinoma is one of the most common gynecologic tumors in the world [1]. Post-operative high-dose-rate brachytherapy with vaginal cylinder to irradiate the vaginal cuff (HDR-VCB) has established itself as adjuvant radiotherapy treatment of early endometrial cancer [2-4].

The goal of HDR-VCB is to reduce local recurrence rates in vaginal cuff, but it may increase normal tissue toxicity [5]. Therefore, it is important to measure the dose received by normal tissues and pelvic organs at risk (OARs) during treatment [6, 7].

Laparoscopic approach to routine procedure for endometrial cancer modifies the technique of suturing the vaginal stump, which can be performed transvaginally [8]. There is a possibility that small bowel loops may remain very close to, and even attached to the inner end of vaginal cuff. Higher doses may be received in HDR-VCB treatment due to the proximity of vaginal cylinder, which cause unwanted intestinal morbidity [9].

Currently, treatment planning with HDR-VCB is based on the use of CT after gynecologic application [10, 11]. In delineation of clinical target volume (CTV), the American Brachytherapy Society (ABS) and GEC-ESTRO (the Groupe Européen de Curiethérapie and the European Society for Radiotherapy and Oncology) recommendations are followed [12, 13]. Clinical target volume, which is considered the upper third portion of the vagina, is usually between 3 cm and 5 cm in length, with longer length.
in cases of adverse histology [6, 14, 15]. The bladder [16], rectum, sigmoid colon [13], and small bowel [13, 17] should be deemed as organs at risk within the pelvis. In current guidelines, there are no recommendations for the use of oral contrast in the small bowel during contouring planning [13]. After laparoscopic surgery, it would help to distinguish small bowel loops from the sigmoid and rectum. Regarding the rectum, enema before cylinder insertion does not influence recto-sigmoid dosimetric parameters [18].

**Non-consensus for HDR-VCB**

There is no consensus on several specific aspects when administering HDR-VCB treatment, such as bladder filling [19], placement of Foley catheter in the bladder [20, 21], amount of volume to fill the bladder [19, 21, 22], and procedure for a precise delimitation of the small bowel, the most radiosensitive organ relative to the bladder, rectum, and sigmoid [19, 23]. In patients undergoing laparoscopic surgery and HDR-VCB, administration of oral barium contrast offers the advantage of clearly defining small bowel loops proximal to the vaginal cuff to differentiate them from other bowel loops in order to evaluate dosimetric consequences in this OAR with different bladder filling. There are no published studies that assess dosimetric impact on OARs by modifying bladder filling in HDR-VCB treatment in laparoscopic surgery and oral barium contrast in the small bowel. Therefore, this was the aim of the present study.

It is worth highlighting that a novel aspect of this study is the use of oral barium contrast in the small bowel during CT treatment planning in HDR-VCB.

**Material and methods**

**Patients**

Between November 2019 and December 2020, 19 women were included in this prospective dosimetric study. Prior approval was obtained from the Hospital’s ethics committee. None of the patients had previously received HDR-VCB or external pelvic radiotherapy. Inclusion criteria were total laparoscopic hysterectomy (TLH) plus bilateral salpingo-oophorectomy and pelvic para-aortic lymphadenectomy, confirmed histology of endometrial carcinoma with no other cancer, age over 18 years, and good performance status. Each patient provided written consent to participate in the study.

Staging of the International Federation of Gynecology and Obstetrics (FIGO) 2009 and pathologic characteristics of the patients are shown in Table 1.

**Table 1. Patients’ characteristics**

| Characteristics | No. of patients |
|-----------------|-----------------|
| Age (years)     |                 |
| ≤ 60            | 6               |
| > 60            | 13              |
| Histology       |                 |
| Endometrioid    | 16              |
| Serous          | 3               |
| Tumor grade     |                 |
| G1              | 11              |
| G2              | 4               |
| G3              | 4               |
| Surgery         |                 |
| TLH + BSO       | 6               |
| TLH + BSO + LNP | 10              |
| TLH + BSO + LNP + LNPR | 3 |
| Stage           |                 |
| IA              | 6               |
| IB              | 13              |
| Cylinder diameter (cm) |       |
| 2.5             | 4               |
| 3.0             | 9               |
| 3.5             | 6               |
| Length treatment (cm) |       |
| 3               | 12              |
| > 3             | 7               |
| Median dose (Gy) |                 |

TLH + BSO = total laparoscopic hysterectomy and bilateral salpingo-oophorectomy, LNP = lymph node pelvic lymphadenectomy, LNPR = lymph node para-aortic lymphadenectomy
and full bladder planning, making CTVs dose distributions identical.

A 5-mm expansion over the cylinder contour was performed automatically in all axes, except for the lower longitudinal, forming CTV. The dose of 7 Gy to CTV was prescribed for 3 cm and 3.5 cm cylinders, and 6.4 Gy for 2.5 cm cylinder, to administer the same equivalent dose (EQD2) to the cylinder surface. One fraction per week was administered. Total administered doses were 21.0 Gy and 19.2 Gy, respectively. Dose calculation in OARs was performed following ICRU 89 standards [24].

Plans were performed with Oncentra Brachy v. 4.5.3 planning system. First, the planning was carried out on empty bladder CT scan. For this purpose, dose points were generated at 0.5 cm from the cylinder surface, following CTV length. Then, the plan dose was optimized and prescribed, so that 100% doses were uniform at these points for source dwell positions set to 0.25 cm. Later, dwell positions and times obtained in empty bladder planning were reproduced on full bladder CT. Calculation algorithm was based on a TG43 formalism, which is the established standard for brachytherapy calculations, and does not consider density differences.

Finally, the treatment was delivered using an $^{192}$Ir gamma radiation source using Nucletron MicroSelectron Afterloader (Elekta Instrument AB; Stockholm, Sweden).

The dosimetric values were expressed as the minimum dose at 0.1 cc, 1.0 cc, and 2.0 cc volume ($D_{0.1cc}$ to $D_{1cc}$) plus exposed OAR, and the dose received by 50% of OAR volume ($D_{50cc}$). For OAR volumes receiving 20% and 50% of the prescribed dose ($V_{20}$ and $V_{50}$ in cc), the dose was delivered at 5 mm from the cylinder surface. The prescribed dose was administered in the first fraction with the bladder previously emptied by Foley catheter, and in the two successive fractions with the bladder empty, without Foley catheter. The rest of sessions were conducted with an empty bladder, with the same dosimetric as set on the first day. Patients not included in this study were treated with an empty bladder using the same dosimetric protocol.

**OARs contouring**

The bladder, rectum, sigmoid, and small bowel were considered OARs, and were contoured as solid organs in 3 dimensions by one physician and checked by another. They were contoured on CT with empty bladder and with full bladder. The rectum was contoured from the anal sphincter to the sigmoid colon area, where the rectum loses its' rounded shape in the axial plane and adopts a vertical orientation. It stops when the colon ascends laterally. The small bowel was contoured using barium contrast as an aid, up to 4 cm above the upper edge of the cylinder.

**Statistics**

The volumes of all specified OARs were determined, and dose-volume histograms generated in empty and full bladder states were compared. We planned the study with a continuous response variable from matched pairs.

Prior data [21] indicated that the difference in the response of bladder $D_{2cc}$ dose pairs is normally distributed, with a standard deviation of 1.22 Gy. According to Guler et al., for a true difference in the mean response of 0.85 Gy in the bladder $D_{2cc}$, we would need to study 19 patients for a significance level of 0.05 and statistical power of 0.8. Statistical evaluation was performed on dosimetric changes produced by anatomical changes, and all statistical analysis were assessed with SPSS software, version 21.0 (SPSS, Chicago, IL, USA). Graphics were made with Microsoft Excel 365®.

**Results**

The mean patient age of the 19 analyzed patients was 58 years (range, 38-81 years). Patients’ characteristics, including FIGO stage (2017), histology, tumor grade, surgery, cylinder size, and dose per fraction are shown in Table 1. The number of fractions treated was 3 in all patients. None of the patients experienced discomfort due to Foley catheter or cylinder insertion. The mean full bladder volume was approximately four times larger compared to empty bladder (248.54 cc vs. 63.77 cc, $p < 0.001$). With an empty bladder, the small bowel generally moved anteriorly, laterally, and superiorly, as presented in Figure 1.

Bladder distension did not have a significant dosimetric impact on the bladder with $D_{2cc}$ from 5.06 to 5.56 Gy ($p = 0.07$), nor on the rectum or sigmoid, but it did have a significant impact on the small bowel, with $D_{2cc}$ from 2.70 Gy to 1.68 Gy ($p < 0.001$) and $D_{50cc}$ from 1.09 to 0.70 Gy with a full bladder (Table 2). $D_{50cc}$ of the bladder was affected by bladder distension from 1.28 to 2.11 Gy, $p < 0.001$. In Figure 2, $D_{2cc}$ and $D_{50cc}$ values for each individual patient are displayed for bladder in Figure 2A and B, and for the small bowel in Figure 2C and D.

**Discussion**

In our study, the dosimetric effect of bladder filling in HDR-BT treatment with distended bladder significantly reduced the highest dose in the small bowel proximal to the vaginal cuff, visualized with oral barium contrast, with no significant change in the bladder, rectum, or sigmoid dose. To our knowledge, this is the first prospective study using barium contrast for small bowel delineation in post-operative HDR-BT treatment of vaginal cuff in patients operated by laparoscopy, facilitating differentiation with other bowel loops.

There are few studies [19-23] comparing dosimetric influence of bladder filling during HDR-VCB planning in OARs, and there are no studies quantifying a difference between using or not using contrast in the small bowel. All published studies are presented in Table 3. Hoskin and Vidler are the first authors to perform a comparative analysis of empty and full bladder. They based their measurements on a 2D bladder height, without evaluating volumetric parameters of the bladder. They found that instillation of 100 ml of water into the bladder decreased the amount of small bowel in high-dose region by 57%, without significantly increasing the
mean maximum bladder dose. Full bladder treatment with at least 100 cc is recommended [22].

Steward et al. investigated dose parameters in CT planning with empty and full bladder on images acquired 1 hour after consumption of 32 oz of water. They reported that bladder distension increased bladder $D_{2cc}$ with no appreciable change in rectal $D_{2cc}$. Sigmoid colon and small bowel dosimetrics were not evaluated. In contrast, our result showed that bladder $D_{2cc}$ was +10% change, but not significantly higher with a full bladder. As the small bowel was not considered, we could not compare data in this OAR [19].

**Table 2.** Mean dosimetric values of bladder and small bowel in full and empty bladder filling

| Mean dosimetric values | Empty bladder | Full bladder | p-value |
|------------------------|--------------|--------------|---------|
| Mean volume bladder (range), cc | 62.18 (25.05-112.3) | 248.0 (156.5-307.0) | < 0.001 |
| Mean volume small bowel (range), cc | 63.48 (26.2-131.7) | 40.63 (23.9-174.4) | < 0.05 |
| $D_{50\%}$ for bladder (range), Gy | 2.11 (1.03-3.63) | 1.28 (0.63-2.18) | < 0.001 |
| $D_{0.1cc}$ for small bowel (range), Gy | 1.09 (0.18-1.78) | 0.70 (0.24-1.8) | < 0.001 |
| $D_{0.1cc}$ for bladder (range), Gy | 6.60 (4.4-8.6) | 7.05 (3.2-9.47) | 0.15 |
| $D_{0.1cc}$ for small bowel (range), Gy | 3.90 (0.34-8.64) | 2.61 (0.97-11.14) | < 0.05 |
| $D_{1cc}$ for bladder (range), Gy | 5.54 (3.4-7.3) | 6.18 (4-7.71) | < 0.05 |
| $D_{1cc}$ for small bowel (range), Gy | 3.07 (0.5-7.8) | 1.97 (0.23-4.26) | < 0.001 |
| $D_{2cc}$ for bladder (range), Gy | 5.06 (2.9-6.66) | 5.56 (2.5-7.36) | 0.07 |
| $D_{2cc}$ for small bowel (range), Gy | 2.70 (0.5-4.81) | 1.68 (0.22-4.06) | < 0.001 |
| $V_{20\%}$ for bladder (range), % | 74.13 (24.23-99.24) | 44.97 (9.13-83.4) | < 0.001 |
| $V_{50\%}$ for small bowel (range), % | 28.98 (0.0-84.6) | 13.75 (0.71-17.41) | < 0.001 |
| $V_{50\%}$ for bladder (range), % | 18.40 (1.13-53.89) | 8.90 (1.16-16.43) | < 0.001 |
| $V_{50\%}$ for small bowel (range), % | 3.91 (0.0-23.9) | 2.18 (0.17-4.9) | 0.14 |

$D_{0.1cc}$ – dose to 0.1 cc; $D_{1cc}$ – dose to 1 cc; $D_{2cc}$ – dose to 2 cc; $D_{50\%}$ – dose to 50% of volume; $V_{20\%}$ – percentage of organ volume receiving ≥ 20% of the prescribed dose; $V_{50\%}$ – percentage of organ volume receiving ≥ 50% of the prescribed dose

**Fig. 1.** Organs at risk (OARs) in axial with full bladder (A) and sagittal with full bladder (B) (small bowel with barium contrast displaced anteriorly, superiorly, and laterally); in axial with empty bladder (C) and sagittal direction with empty bladder (D) (small bowel loops with barium contrast located very close to the cylinder)
Hung et al. evaluated OARs doses to the rectum, bladder, sigmoid, and small bowel without a contrast. $D_{2\text{cc}}$ (1.179 cGy vs. 1.246 cGy, $p = 0.11$) and $D_{50\%}$ (441 cGy vs. 279 cGy, $p = 0.001$) of small bowel with bladder filled with 180 cc via Foley catheter, resulted in a significant dose reduction with no significant changes in the bladder, rectum, or sigmoid. Our dosimetric calculation is in agreement with these findings, although the dose recorded at 2 cc bladder with full bladder was slightly higher, it was not significant. In addition, the dose to the small bowel was significantly lower with a full bladder. Their study was performed without oral contrast in small bowel. The authors advised treatment with distended bladder [23].

In a study by Kobzda et al., the bladder was filled with a 400 ml, ingested 40 min before CT. They described that bladder $D_{2\text{cc}}$ significantly decreased with empty bladder (4.9 Gy vs. 4.6 Gy, $p < 0.05$), while volumetric doses ($V_{50}$ and $V_{80}$) were significantly higher in the empty organ. Our results show a similar trend, but without statistical significance. This difference could be explained by a different volume of bladder filling used (400 cc vs. 180 cc). In the small bowel, it was associated with a significant reduction of the intestinal dose of $D_{2\text{cc}}$ (4.1 Gy vs. 4.6 Gy, $p < 0.05$). Their findings are consistent with the present results. Moreover, the authors recommended treatment with a full bladder [20].

In a study, Guler et al. assessed patients who underwent initial CT with an empty bladder and then, sterile saline (180 ml) was infused through a Foley catheter. Two-thirds of the vaginal cuff was treated. OARs, such as the bladder, rectum, sigmoid, and small bowel without contrast were analyzed. Full bladder produced a significant 18.7% increase in $D_{2\text{cc}}$ in the bladder (5.40 Gy vs. 4.55 Gy, $p < 0.05$), but not in the rectum. The reduction in sigmoid and small bowel was not significant. The results of our study are not consistent with these findings. One cause could be that their treatment activated two thirds of the vaginal cylinder, while in our protocol, only one third was activated. The other also did not use contrast in the small bowel [21].

Our dosimetric study has some limitations, including small number of cases, which makes it difficult to generalize the results. This was a dosimetric study that did not intend to draw clinical conclusions. The obtained data should be correlated with short- and long-term morbidity analyses, quality of life questionnaires, and in vivo dosimetry studies. Such a correlation could help to assess the doses to OARs, suggesting further research development.

Conclusions

In patients undergoing laparoscopic surgery for endometrial cancer treated with HDR-VCB, full bladder reduces a higher dose to the small bowel previously visualized with oral barium contrast, without a clinically relevant dose increase in the bladder and no dose increase in the sigmoid or rectum. Treatment with full bladder appears more beneficial dosimetrically due to possible impact on this risk organ.

![Fig. 2. Values $D_{2\text{cc}}$ (Gy) and $D_{50\%}$ for individual case. Dashed line: empty bladder, red line: full bladder. A) $D_{2\text{cc}}$ bladder; B) $D_{50\%}$ bladder; C) $D_{2\text{cc}}$ small bowel; D) $D_{50\%}$ small bowel](image-url)
### Table 3. Authors and studies on dosimetric impact of bladder filling in OARs

| Autor, year [Ref.] | No. of patients, type of tumor, type surgery | Foley catheter use of oral contrast | CT (empty and full bladder); use of oral contrast | No. of doses and fx. | Length of vagina treated | Organ at risk analyzed | Dosimetric and volumetric parameters | Results, full vs. empty bladder | Conclusions |
|---------------------|---------------------------------------------|------------------------------------|-----------------------------------------------|---------------------|------------------------|-----------------------|-----------------------------------|---------------------------------|-------------|
| Hoskin et al., 2000 [22] | 30 patients, gynecologic carcinoma, not specified | Yes 1. Rx pa. and lateral with catheter with balloon, and hypaque and barium in rectum 2. Serial CT scan (5 mm) with empty and full bladder with 35 cc, 70 cc, and 100 cc; no contrast | 5.5 Gy at 0.5 cm x 4 fx. 1/3 upper vagina | Bladder, small bowel | Bladder volume, bladder area, small bowel area, bladder mean max. dose, bladder height | Bladder dose not affected by volume; small bowel volume within high-dose treatment region decreased 57.5% with 100 ml bladder volume | VCB should be undertaken with a bladder volume of at least 100 ml, which will considerably reduce the amount of small bowel in irradiation volume, with no increase of the bladder dose |
| Stewart et al., 2008 [19] | 20 patients, gynecologic carcinoma, not specified | No 1. fx: bladder comfort filling 2. fx: full bladder with 950 cc 3. fx: empty bladder, no contrast | EBRT + BT (6 Gy x 2 fx.) or BT only (6 Gy x 5 fx.) Upper half of the vagina (mean, 7 cm) | Bladder, rectum and urethra, maximum bladder point (MBP), maximum rectal point (MRP) | Bladder: V70cc, V50cc, surface area: 50 cc, D2cc, MRP, cc, and Gy Rectum: D2cc, MRP, cc, and Gy | Bladder V70, V50, SA50, and D3cc were significantly lower for the empty bladder than for the full bladder. Bladder filling did not alter the volume or surface area of rectum irradiated | Patients receiving HDR-VCB should be treated with an empty bladder if feasible. MBP correlates well with volumetric assessments of the bladder dose and provides a non-invasive method for reporting MBP using 3D imaging |
| Hung et al., 2011 [23] | 12 patients, endometrium, cervix and ovarian, primary or recurrence, not specified | Yes: 180 cc 2-5 fx, 5 Gy at 0.5 cm | Yes: empty bladder and full 180 cc, no contrast | Bladder, rectum, sigmoid, small bowel | D2cc, D3cc, ICRU points, cylinder-to-bowel distance | Full bladder: D3cc in the mean small bowel significantly decreased, and the bladder did not. Full bladder: D3cc decreased for the bladder and small bowel. Not for rectum and sigmoid | Distended bladder preferentially reduced high-dose to the small bowel around the vaginal cuff without a significant change in dose to the bladder, rectum, or sigmoid |
| Kobzda et al., 2014 [20] | 45 patients (36 patients: only VCB), all stages endometrium, not specified | No previous BT, 400 ml intake 4 Gy x 6 fx or 6 Gy x 3 fx | Yes: CT-full bladder, and after CT-empty bladder after (post-urinating), not contrast | 1/3 upper vagina | Bladder, rectum, sigmoid, small bowel | D0.1cc, D2cc, to bladder rectum and bowel, V50%, V90%, EQD2 of OAR | D0.1cc and D2cc of the bladder were lower in the empty state. V50% and V90% were to be higher in the empty state. The dose to the empty bladder was lower than when the bladder is full. Protection of more radiosensitive bowels suggested treating the patients in the full state of the bladder |
### Table 3. Cont.

| Author, year [Ref.] | No. of patients, type of tumor, type surgery | Foley catheter | CT (empty and full bladder); use of oral contrast | No. of doses and fx. | Length of vagina treated | Organ at risk analyzed | Dosimetric and volumetric parameters | Results, full vs. empty bladder | Conclusions |
|---------------------|---------------------------------------------|----------------|-----------------------------------------------|---------------------|-------------------------|------------------------|----------------------------------|-----------------------------|--------------------------|
| Guler et al., 2014 [21] | 15 patients, early stage endometrial cancer, total abdominal hysterectomy | Yes: 180 cc | Yes: CT-empty bladder and CT-full bladder (180 cc); Not contrast | 5 Gy × 5 fx. | 3-5 cm of vagina | Bladder, rectum, sigmoid, small bowel | D0.1cc, D0.2cc, D0.5cc, D1cc, D2cc, D50% | Bladder distention appreciably impacted dosimetry of the bladder, sigmoid colon, and small bowel, but dosimetry of the rectum was unaffected | The combination of a full bladder and an empty rectum may cause significant unwanted increases in VCB dosing of the bladder, without significantly impacting sigmoid colon and small bowel exposures; Better empty bladder |
| Salas et al., 2021 [present study] | 19 patients, early-stage endometrial cancer, total laparoscopic hysterectomy | Yes: 180 cc | Yes: CT-empty bladder and CT-full bladder (180 cc); contrast in the bladder, and oral barium contrast in small bowel | 7 Gy × 3 fx. | 3 cm of upper vagina (endometrioid), 5 cm of upper vagina (serous) | Bladder, rectum, sigmoid, small bowel | D0.1cc, D0.2cc, D0.5cc, V10%, V20%, V50% | Bladder D2cc was not significantly higher with the full bladder; V50% was lower; small bowel D2cc and D50% were higher with the empty bladder; V20% dose was not affected by the dose | Full bladder reduced high-dose to the small bowel during HDR-VCB with no significantly increased doses in the bladder, and not impacted the rectum or sigmoid; Treatment with a full bladder was advisable |

GARs — organs at risk; Rx — X-ray; CT — computed tomography; VCB — vaginal cuff brachytherapy; HDR-VCB — high-dose-rate vaginal cuff brachytherapy; cc — cubic centimeters; fx. — fraction; EBRT — external beam radiation therapy; BT — brachytherapy; Gy — Gray; D0.1cc — dose to 0.1 cc of organ; D1cc — dose to 1 cc; D2cc — dose to 2 cc; D50% — dose to 50% of volume; V10%, V20%, V50%, V70%, V80% — percentage of organ volume receiving ≥10%, ≥20%, ≥50%, ≥70%, ≥80% of the prescribed dose; V10%, V20%, V50% — percentage of organ volume receiving ≥10%, ≥20%, ≥50% of the prescribed dose; MBR — percentage of organ volume receiving ≥80% of the prescribed dose; ICRU — International Commission on Radiation Units; MBP — maximum bladder point; MRP — maximum rectal point; SA50 — surface area of bladder receiving ≥50% of dose; EQD2 — equivalent dose in 2 Gy per fraction.
Disclosure
The authors report no conflict of interest.

References
1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
2. Colombo N, Creutzberg C, Amant F et al., ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27: 16-41.
3. Concini N, Matias-Guiu X, Vergote I et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12-39.
4. Serkies K, Baczkowska-Waliszewska Z. Adjuvant vaginal cuff brachytherapy in surgically treated endometrial carcinoma patients – in view of the recent evidence. J Contemp Brachytherapy 2021; 13: 221-230.
5. Autorino R, Tagliabue L, Campitelli M et al. EROS study: Evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis. J Contemp Brachytherapy 2018; 10: 315-320.
6. Small W, Beriwal S, Dementes DJ et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 2012; 11: 58-67.
7. Sabater S, Andres I, Lopez-Honrubia V et al. Vaginal cuff brachytherapy in endometrial cancer – a technically easy treatment? Cancer Manag Res 2017; 9: 351-362.
8. Uccella S, Malzoni M, Cromi A et al. Laparoscopic vs transvaginal cuff closure after total laparoscopic hysterectomy: a randomized trial by the Italian Society of Gynecologic Endoscopy. Am J Obstet Gynecol 2018; 218: 500.e1-500.e13.
9. Caon J, Holloway C, Dubash R et al. Evaluating adjacent organ radiation doses from postoperative intracavitary vaginal vault brachytherapy for endometrial cancer. Brachytherapy 2014; 13: 94-99.
10. Harkenrider MM, Grover S, Erickson BA et al. Vaginal brachytherapy for postoperative endometrial cancer: 2014 Survey of the American Brachytherapy Society. Brachytherapy 2016; 15: 23-29.
11. Gulitekin M, Yilmaz MT, Biltekin F et al. Adjuvant vaginal cuff brachytherapy: dosimetric comparison of conventional versus 3-dimensional planning in endometrial cancer. J Contemp Brachytherapy 2021; 12: 601-605.
12. Small W, Erickson B, Kwakwa F. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: Current status of vaginal brachytherapy. Int J Radiat Oncol Biol Phys 2005; 63: 1502-1507.
13. Hoskin P, Hellebust TP, Nout R et al. Endometrial cancer. In: van Limbergen E, R. Potter, P. Hoskin (Eds.), The GEC ESTRO Handbook of Brachytherapy. Brussels, December 2019.
14. Eldredge-Hindy HB, Eastwick G, Anne PR et al. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. J Contemp Brachytherapy 2014; 6: 262-270.
15. Harkenrider MM, Block AM, Alektiar KM et al. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy 2017; 16: 95-108.
16. Nag S, Erickson B, Parikh S et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 2000; 48: 779-790.
17. Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2010; 76: 104-109.
18. Sikorska K, Zolciak-Siwinska A, Kowalczyk A et al. Dosimetric evaluation of vaginal cuff brachytherapy planning in cervical and endometrial cancer patients. J Contemp Brachytherapy 2020; 12: 248-251.
19. Stewart AJ, Cormack RA, Lee H et al. Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy. Int J Radiat Oncol Biol Phys 2008; 72: 843-848.
20. Kobzda JD, Cicewska-Wozniak E, Michalska M et al. Three-dimensional dosimetry of the full and empty bladder in high dose rate vaginal cuff brachytherapy. Int J Gynecol Cancer 2014; 24: 923-927.
21. Guler OC, Onal C, Acibucu I. Effects of bladder distension on dose distribution of vaginal vault brachytherapy in patients with endometrial cancer. J Contemp Brachytherapy 2014; 6: 371-376.
22. Hoskin PJ, Vidler K. Vaginal vault brachytherapy: the effect of varying bladder volumes on normal tissue dosimetry. Br J Radiol 2000; 73: 864-866.
23. Hung J, Shen S, De Los Santos JF et al. Image-based 3D treatment planning for vaginal cylinder brachytherapy: Dosimetric effects of bladder filling on organs at risk. Int J Radiat Oncol Biol Phys 2012; 83: 980-985.
24. Prescribing, recording, and reporting brachytherapy for cancer of the cervix. J ICRU 2013; 13: NP.